Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.25M | 12.09M | -88.82M | -85.97M | -87.65M |
| Total Depreciation and Amortization | 1.70M | 1.58M | 1.42M | 1.16M | 1.24M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.83M | 5.55M | 98.20M | 100.38M | 101.04M |
| Change in Net Operating Assets | -21.44M | -22.86M | -8.31M | -7.24M | 3.72M |
| Cash from Operations | -6.65M | -3.64M | 2.48M | 8.33M | 18.36M |
| Capital Expenditure | -2.21M | -2.32M | -4.70M | -5.99M | -7.01M |
| Sale of Property, Plant, and Equipment | 352.00K | 401.00K | 430.00K | 798.00K | 714.00K |
| Cash Acquisitions | -- | -- | 5.46M | 5.46M | 5.46M |
| Divestitures | -- | -- | -566.00K | -566.00K | -566.00K |
| Other Investing Activities | -8.84M | -17.97M | -17.16M | -19.26M | -17.94M |
| Cash from Investing | -10.70M | -19.88M | -16.54M | -19.55M | -19.33M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.45M | 2.64M | 1.31M | 933.00K | 658.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 2.50M | 2.50M | 2.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -657.00K | -536.00K | -169.00K | -119.00K | -- |
| Cash from Financing | 2.79M | 2.10M | 3.64M | 3.31M | 3.16M |
| Foreign Exchange rate Adjustments | -177.00K | -273.00K | 213.00K | 278.00K | -544.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.74M | -21.70M | -10.21M | -7.63M | 1.64M |